Kenneth O'Byrne and colleagues examined whether candidate biomarkers were predictive for the efficacy of chemotherapy plus cetuximab for advanced non-small-cell lung cancer. Patients with tumours expressing PTEN who were given chemotherapy plus cetuximab had a median survival of 11·4 months (95% CI 8·6–13·6) versus 6·8 months (5·9–12·7), for those with tumours not expressing PTEN (hazard ratio [HR] 0·80, 95% CI 0·55–1·16, p=0·24). For patients given chemotherapy without cetuximab, the median survival was 11·0 months (9·2–12·6) for patients with tumours expressing PTEN versus 9·3 months (7·6–11·9) for patients with tumours not expressing PTEN (HR 0·77, 0·54–1·10, p=0·16).
Júlio Leonardo B. Pereira
No comments:
Post a Comment